Drs. Emily-Lauren Simms and Nicolas Vendeville present their talk, “What’s hot at ISN and CSN 2024 - Fellows ‘show and tell,’” as part of BC Renal and UBC’s province-wide rounds.
0:09:00 - Dr. Simm’s highlights
Dr. Simms starts by providing highlights from the 2024 International Society of Nephrology (ISN) meeting in Buenos Aires and 2024 Canadian Society of Nephrology (CSN) meeting in Montreal, including some presentations by BC Renal members.
0:13:00 - Emerging drugs
Dr. Simms provides updates on emerging drugs for kidney disease, including finerenone, ozempic, and semaglutide. Of note, the FLOW study investigating semaglutide was stopped early due to positive results, where every single primary endpoint was met (e.g., a 24% reduction in risk of kidney disease progression and kidney/cardiovascular death). She highlights some subsequent studies that will delve further into the effects of this medication.
0:19:00 - Anemia guidelines
Dr. Simms notes some upcoming KDIGO guidelines on anemia are very different from earlier, 2012 guidelines, and will change the way anemia is treated if accepted. She provides an overview of the PIVOTAL study exploring intravenous iron in kidney patients, noting that participants with higher ferrin levels reported feeling better. Dr. Simms provides an overview of new, tentative targets in the upcoming KDIGO guidelines, including when to refer to patients to a specialist.
0:27:00 - ANCA-Associated Vasculitis guidelines
She then talks about when PLEX-Y could be used to treat ANCA-associated vasculitis if patients meet certain criteria. New data also point to Avacopan as non-steroidal option, she notes.
0:31:00 - Dr. Vendeville’s highlights
Dr. Vendeville begins by providing his highlights for the ISN meeting in Buenos Aires, for example a talk on Xenotransplantation; and menopause and kidney transplants.
0:34:00 - Hypertension management
He engages in an interactive debate as to achieve systolic blood pressure targets less than 120 in kidney patients. Dr. Vendeville then highlights different studies, including the SRPINT trial, to explore treating blood pressure in kidney patients, noting that controlling blood pressure under 120 can reduce deaths, but involve adverse side effects. At World Congress, he attended an interesting debate between two experts, and shares their pro and con arguments in greater detail. Dr. Vendeville then re-polls the PWR audience, with some people shifting away from their original answer to strive to achieve BP targets below 120. He emphasizes the need for more randomized control trials on this topic, and suggests that more debate-like approaches, such as this one, could be done to find answers.
0:49:00 - Q&A
Dr. Vendeville and Dr. Simms take questions from the audience.
26 авг 2024
